IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.270
0.00 (0.00%)
Aug 13, 2025, 4:00 PM - Market open
Company Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences, Inc.
| Country | United States |
| Founded | 1993 |
| IPO Date | Sep 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Mary Harler |
Contact Details
Address: 325 East Middlefield Road Mountain View, California 94043 United States | |
| Phone | 650 965 7873 |
| Website | igmbio.com |
Stock Details
| Ticker Symbol | IGMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001496323 |
| CUSIP Number | 449585108 |
| ISIN Number | US4495851085 |
| Employer ID | 77-0349194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mary Beth Harler M.D. | Chief Executive Officer and Director |
| Paul C. Graffagnino J.D. | Senior Vice President of Legal Affairs |
| Suzette Tauber | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 16, 2025 | SC 14D9 | Filing |
| Jul 16, 2025 | SC TO-T | Filing |
| Jul 9, 2025 | SCHEDULE 13G | Filing |
| Jul 1, 2025 | SC14D9C | Filing |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |